Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study
- PMID: 17545304
- DOI: 10.1093/hmg/ddm094
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study
Abstract
Animal and human studies suggest that both secretory PLA2 (sPLA2)-V and sPLA2-IIA (encoded, respectively, by the neighbouring PLA2G5 and PLA2G2A genes) contribute to atherogenesis. Elevated plasma sPLA2-IIA predicts coronary heart disease (CHD) risk, but no mass assay for sPLA2-V is available. We previously reported that tagging single nucleotide polymorphism (tSNP) haplotypes of PLA2G2A are strongly associated with sPLA2-IIA mass, but not lipid levels. Here, we use tSNPs of the sPLA2-V gene to investigate the association of PLA2G5 with CHD risk markers. Seven PLA2G5 tSNPs genotypes, explaining >92% of the locus genetic variability, were determined in 519 patients with Type II diabetes (in whom PLA2G2A tSNP data was available), and defined seven common haplotypes (frequencies >5%). PLA2G5 and PLA2G2A tSNPs showed linkage disequilibrium (LD). Compared to the common PLA2G5 haplotype, H1 (frequency 34.9%), haplotypes H2-7 were associated with overall higher plasma LDL (P < 0.00004) and total cholesterol (P < 0.00003) levels yet lower oxLDL/LDL (P = 0.006) and sPLA2-IIA mass (P = 0.04), probably reflecting LD with PLA2G2A. Intronic tSNP (rs11573248), unlikely itself to be functional, distinguished H1 from LDL-raising haplotypes and may mark a functional site. In conclusion, PLA2G5 tSNP haplotypes demonstrate an association with total and LDL cholesterol and oxLDL/LDL, not seen with PLA2G2A, thus confirming distinct functional roles for these two sPLA2s.
Similar articles
-
Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.Circ Cardiovasc Genet. 2014 Apr;7(2):144-50. doi: 10.1161/CIRCGENETICS.113.000271. Epub 2014 Feb 21. Circ Cardiovasc Genet. 2014. PMID: 24563418 Free PMC article.
-
Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study.Hum Mol Genet. 2006 Jan 15;15(2):355-61. doi: 10.1093/hmg/ddi453. Epub 2005 Dec 20. Hum Mol Genet. 2006. PMID: 16368710
-
The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.Gene. 2015 Jun 10;564(1):29-34. doi: 10.1016/j.gene.2015.03.030. Epub 2015 Mar 17. Gene. 2015. PMID: 25794429
-
Phospholipase A2 and small, dense low-density lipoprotein.Curr Opin Lipidol. 2000 Oct;11(5):465-71. doi: 10.1097/00041433-200010000-00004. Curr Opin Lipidol. 2000. PMID: 11048889 Review.
-
Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases.Curr Mol Med. 2001 Dec;1(6):739-54. doi: 10.2174/1566524013363258. Curr Mol Med. 2001. PMID: 11899260 Review.
Cited by
-
The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).J Lipid Res. 2009 Apr;50(4):623-9. doi: 10.1194/jlr.M800361-JLR200. Epub 2008 Nov 21. J Lipid Res. 2009. PMID: 19029066 Free PMC article.
-
Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.Circ Cardiovasc Genet. 2014 Apr;7(2):144-50. doi: 10.1161/CIRCGENETICS.113.000271. Epub 2014 Feb 21. Circ Cardiovasc Genet. 2014. PMID: 24563418 Free PMC article.
-
Role of secretory phospholipases in atherogenesis.Curr Atheroscler Rep. 2008 Jun;10(3):252-9. doi: 10.1007/s11883-008-0039-6. Curr Atheroscler Rep. 2008. PMID: 18489854 Review.
-
Distinct expression pattern of the full set of secreted phospholipases A2 in human colorectal adenocarcinomas: sPLA2-III as a biomarker candidate.Br J Cancer. 2008 Feb 12;98(3):587-95. doi: 10.1038/sj.bjc.6604184. Epub 2008 Jan 22. Br J Cancer. 2008. PMID: 18212756 Free PMC article.
-
A new era of secreted phospholipase A₂.J Lipid Res. 2015 Jul;56(7):1248-61. doi: 10.1194/jlr.R058123. Epub 2015 Mar 24. J Lipid Res. 2015. PMID: 25805806 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials